glp-1 drug novo nordisk Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say Novo Nordisk Finds Medicare Patients

JACC: Basic To Trans Sci (2018) 3:84457

Bottom line: CagriSema could become the go-to option for patients who want more than Ozempic alone can offer, especially those struggling with fatty liver disease or stubborn appetite control

Prescription GLP-1 Medications: Understanding the Differences Because the brand markets NuraPatch as a "GLP-1 alternative," understanding how botanical patches differ from prescription GLP-1 medications is essential for setting accurate expectations

100 This randomized placebo-controlled trial included 5380 patients and had a median follow-up of 18 months

Firstly, the majority of reports lack evidence establishing a causal link between the reported AE and drug exposure